1 Brenner R, Waeber B, Allemann Y. Medical treatment of hypertension in Switzerland. The 2009 Swiss Hypertension Survey (SWISSHYPE). Swiss Med Wkly. 2011;141:w13169.
2 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.
3 Leitlinie Arterielle Hypertonie 2015. Schweizerische Hypertoniegesellschaft SHG, Bern. Abrufbar unter:
www.swisshypertension.ch
4 De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.
5 Grigoryan L, Pavlik VN, Hyman DJ. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. J Am Soc Hypertens. 2013;7:471–6.
6 Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, et al. CRIC Study Investigators. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016;67:387–96.
7 Chmiel C, Wang M, Senn O, Del Prete V, Zoller M, Rosemann T, Steurer-Stey C. Uncontrolled arterial hypertension in primary care-patient characteristics and associated factors. Swiss Med Wkly. 2012;142:w13693.
8 Braam B, Taler SJ, Rahman M, Fillaus JA, Greco BA, Forman JP, et al. Recognition and management of resistant hypertension. Clin J Am Soc Nephrol. 2017;12:524–35.
9 Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386:1588–98.
10 Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66:126–33.
11 Grossman A, Messerli FH, Grossman E. Drug induced hypertension – an unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763(Pt A):15–22.
12 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–300.
13 Därr R, Lenders JW, Hofbauer LC, Naumann B, Bornstein SR, Eisenhofer G. Pheochromocytoma – update on disease management. Ther Adv Endocrinol Metab. 2012;3:11–26.
14 Van der Niepen P, Rossignol P, Lengelé JP, Berra E, Sarafidis P, Persu A. Renal artery stenosis in patients with resistant hypertension: Stent it or not? Curr Hypertens Rep. 2017;19: 5. Abrufbar unter:
https://doi.org/10.1007/s11906-017-0703-8.
15 Textor SC. Renal arterial disease and hypertension. Med Clin North Am. 2017;101:65–79.
16 Gnädiger M, Sebo P, Haller DM, Muggli F, Pechère A. Die nichtinvasive Blutdruckmessung Swiss Med Forum 2016;16:816–22.
17 Denolle T, Eon Y, Le Néel H, Seignard H, Battini J. Programme régional d’amélioration de la prise en charge en médecine générale du patient hypertendu. Arch Mal Coeur Vaiss. 2005;98:761–6.
18 Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691–7.
19 M. Burnier. Drug adherence in hypertension. Pharmacol Res. 2017;125(Pt B):142–9.
20 Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. Evaluation de l’observance du traitement antihypertenseur par un questionnaire: mise au point et utilisation dans un service spécialisé. Presse Med. 2001;30:1044–8
21 Rottlaender D, Scherner M, Schneider T, Erdmann E. Multimedikation, Compliance und Zusatzmedikation bei Patienten mit kardiovaskulären Erkrankungen. Dtsch Med Wochenschr. 2007;132:139–44.
22 Sandbaumüter FA, Haschke M, Vogt B, Bohlender J. Indexed plasma drug concentrations for drug adherence screening in hypertensive patients. Ann Cardiol Angeiol (Paris). 2018;67:119–26.
23 Swissmedic. Schweizerisches Heilmittelinstitut. Abrufbar unter:
www.swissmedicinfo.ch.
24 Gobin N, Wuerzner G, Waeber B, Burnier M. Ambulante 24-Stunden-Blutdruckmessung. Swiss Med Forum 2012;12:600–7.
25 Liu L, Cao Q, Guo Z, Dai Q. Continuous positive airway pressure in patients with obstructive sleep apnea and resistant hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens. 2016;18:153–8.
26 Morganti A, Mancia G. Resistant hypertension: Renal denervation or intensified medical treatment? Eur J Intern Med. 2018;50:6–11.
27 Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.
28 Volpe M, Tocci G, Bianchini F, De Rosa M, Fedozzi E, Covezzoli A, et al. Aliskiren Registry. Use of aliskiren in a ‘real-life’ model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens. 2012;30:194–203.
29 The Seventh Report of the Joint National Committee on Treatment of High Blood Pressure; U.S. National Institutes of Health (NIH), NIH Publication No. 03-5233; Bethesda (MD), 2003.